Sets of traits are notoriously unreliable and somewhat unscientific approach but they can serve you well. In any case we do not have anything better.
Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting.
Daily left prefrontal repetitive transcranial magnetic stimulation rTMS recently received Food and Drug Administration FDA approval for the treatment of depression and offers an alternative to traditional approaches.
This approval was based on a study using stimuli per day 15, stimuli per week in adults with unipolar depression not taking antidepressant medications. Several meta-analyses suggest a dose-response relationship with TMS.
This study was carried out before US FDA approval to test the safety, tolerability, and effectiveness of adjunctive high-dose left prefrontal rTMS in a clinical setting with particular attention to safety of higher doses and potential interactions with antidepressant medications, speed of response, and effects on suicidality.
We enrolled 19 patients who were in a current major depressive episode with treatment-resistant unipolar or bipolar depression and treated them in their acute episode and in a maintenance fashion for 18 months. All patients continued antidepressant medication throughout the rTMS treatment; thus rTMS was an adjunctive treatment.
We measured adverse effects, depression, quality of life, suicidal ideation, and social and physical functioning. These higher rTMS doses were well tolerated without significant adverse effects or adverse events.
All measured dimensions showed improvement, with many showing improvement in 1 to 2 weeks. These uncontrolled data suggest that higher doses of daily left prefrontal rTMS may safely be used in outpatients with major depressive episode even as an adjunctive treatment.
To review systematically the main clinical trials on the pharmacological treatment of bipolar disorder and to make a critical analysis of their methodological aspects. Randomized, double-blind, placebo-controlled clinical trials on the pharmacological treatment of bipolar disorder were selected.
Besides, according to our criteria, samples had to consist of at least patients and experimental drug had to be used as monotherapy.
All drugs currently indicated for mania, bipolar depression and maintenance treatment of bipolar disorder were more effective than placebo in at least one clinical trial.
However, these studies had highly selected samples, high dropout rates and low response rates. Modern clinical trials on pharmacological treatment of bipolar disorder have important methodological limitations. So, their results should be taken with caution. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression.
Lamotrigine and quetiapine are commonly used in bipolar disorder, but there are no published systematic studies of their use in combination for treatment-resistant bipolar depression. We studied 39 trials in outpatients 15 with bipolar I disorder, 22 with bipolar II disorder, and 1 with bipolar disorder not otherwise specified; 1 patient had 2 trials with depression resistant to quetiapine or lamotrigine who were taking a mean of 1.
Patients were given either open-label lamotrigine or quetiapine naturalistically, for up to 12 weeks of combination therapy. Lamotrigine mean dose, Approximately one-fifth of patients discontinued therapy The findings of this uncontrolled open pilot study must be viewed with caution.
However, randomized, double-blind, placebo-controlled studies are warranted to confirm the possibility that combination therapy with lamotrigine and quetiapine is effective and well tolerated in patients with treatment-resistant bipolar depression.
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: In two previous manuscripts, we described the efficacy of lamotrigine versus placebo as add-on to lithium followed by the addition of paroxetine in nonresponders in the short-term treatment of bipolar depression.
In this paper we describe the long-term 68 weeks outcome of that study. A total of bipolar depressed patients receiving lithium were randomized to addition of lamotrigine or placebo. After eight weeks, paroxetine was added to nonresponders for another eight weeks.
Responders continued medication and were followed for up to 68 weeks or until a relapse or recurrence of a depressive or manic episode. After eight weeks, the addition of lamotrigine to lithium was significantly more efficacious than addition of placebo, while after addition of paroxetine in nonresponders both groups further improved with no significant difference between groups at week During follow-up the efficacy of lamotrigine was maintained: In patients with bipolar depression, despite continued use of lithium, addition of lamotrigine revealed a continued benefit compared to placebo throughout the entire study.
Epub Oct 5. Antidepressants for the acute treatment of bipolar depression: The role of antidepressants in the acute treatment of bipolar depression remains a contentious issue.
A previous meta-analysis of randomized controlled trials RCTs concluded that antidepressants were effective and safe for bipolar depression. Several trials published since then suggest that antidepressants may not be as beneficial as previously concluded.
The current systematic review and meta-analyses reexamine the efficacy and safety of antidepressant use for the acute treatment of bipolar depression. Databases of trial registries were also searched for unpublished RCTs. These searches were supplemented by hand searches of relevant articles and review articles.
Main outcome measures were clinical response, remission, and affective switch. These studies were combined with earlier studies for a total of 15 studies containing 2, patients.The entries detail the trials, tribulations, and struggles with my parents in regard to Borderline Personality Disorder and Narcissistic Personality Disorder.
Professional resources are quoted and referenced for an analysis and research basis. Severe attention disorder linked with drug abuse.
Homelessness knowledge and attitudes regarding the management of clients with a diagnosis of borderline personality disorder (BPD) aimed to obtain baseline data to provide direction for developing planned education and determining staff willingness to participate in such training.
A Borderline personality disorder (BPD) is characterized by severe disruption of interpersonal relationships, yet very little research has examined the relationship between maternal BPD and. A Research on Measuring the Correlation of Bipolar Personality Disorder (BPD) Symptoms in Couples.
1, words. 4 pages.
The Effects of Bipolar Disorder on the Human Brain and Behavior. words. 3 pages. Study Shows Bipolar Disorder Can Be Attributed to Heredity. words. 3 pages. EPPP > AR Exam 2 - > Flashcards Research examining methods of informing children with cancer about their illness suggests that The majority of individuals diagnosed with Borderline Personality Disorder (BPD) demonstrate significant reduction or remission of symptoms .
Though longstanding clinical observation reflected in the DSM-IV suggests that the rage characteristic of borderline personality disorder (BPD) often appears in response to perceived rejection, the role of perceived rejection in triggering rage in BPD has never been empirically tested.